Your browser doesn't support javascript.
Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct.
Mykytyn, Anna Z; Rissmann, Melanie; Kok, Adinda; Rosu, Miruna E; Schipper, Debby; Breugem, Tim I; van den Doel, Petra B; Chandler, Felicity; Bestebroer, Theo; de Wit, Maurice; van Royen, Martin E; Molenkamp, Richard; Oude Munnink, Bas B; de Vries, Rory D; GeurtsvanKessel, Corine; Smith, Derek J; Koopmans, Marion P G; Rockx, Barry; Lamers, Mart M; Fouchier, Ron A M; Haagmans, Bart L.
  • Mykytyn AZ; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
  • Rissmann M; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
  • Kok A; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
  • Rosu ME; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
  • Schipper D; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
  • Breugem TI; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
  • van den Doel PB; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
  • Chandler F; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
  • Bestebroer T; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
  • de Wit M; Department of Neurology, Erasmus University Medical Center, Rotterdam, Netherlands.
  • van Royen ME; Department of Pathology, Erasmus University Medical Center, Rotterdam, Netherlands.
  • Molenkamp R; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
  • Oude Munnink BB; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
  • de Vries RD; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
  • GeurtsvanKessel C; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
  • Smith DJ; Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge CB2 3EJ, UK.
  • Koopmans MPG; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
  • Rockx B; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
  • Lamers MM; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
  • Fouchier RAM; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
  • Haagmans BL; Viroscience Department, Erasmus Medical Center, Rotterdam, Netherlands.
Sci Immunol ; 7(75): eabq4450, 2022 09 23.
Article in English | MEDLINE | ID: covidwho-1901912
ABSTRACT
The emergence and rapid spread of SARS-CoV-2 variants may affect vaccine efficacy substantially. The Omicron variant termed BA.2, which differs substantially from BA.1 based on genetic sequence, is currently replacing BA.1 in several countries, but its antigenic characteristics have not yet been assessed. Here, we used antigenic cartography to quantify and visualize antigenic differences between early SARS-CoV-2 variants (614G, Alpha, Beta, Gamma, Zeta, Delta, and Mu) using hamster antisera obtained after primary infection. We first verified that the choice of the cell line for the neutralization assay did not affect the topology of the map substantially. Antigenic maps generated using pseudo-typed SARS-CoV-2 on the widely used VeroE6 cell line and the human airway cell line Calu-3 generated similar maps. Maps made using authentic SARS-CoV-2 on Calu-3 cells also closely resembled those generated with pseudo-typed viruses. The antigenic maps revealed a central cluster of SARS-CoV-2 variants, which grouped on the basis of mutual spike mutations. Whereas these early variants are antigenically similar, clustering relatively close to each other in antigenic space, Omicron BA.1 and BA.2 have evolved as two distinct antigenic outliers. Our data show that BA.1 and BA.2 both escape vaccine-induced antibody responses as a result of different antigenic characteristics. Thus, antigenic cartography could be used to assess antigenic properties of future SARS-CoV-2 variants of concern that emerge and to decide on the composition of novel spike-based (booster) vaccines.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Sci Immunol Year: 2022 Document Type: Article Affiliation country: Sciimmunol.abq4450

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Sci Immunol Year: 2022 Document Type: Article Affiliation country: Sciimmunol.abq4450